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Abstract
Background: Hypertrophic cardiomyopathy (HCM) due to mutations in genes encoding sarcomere proteins is most
commonly inherited as an autosomal dominant trait. Since nearly 50% of HCM cases occur in the absence of a family history,
a recessive inheritance pattern may be involved.
Methods: A pedigree was identified with suspected autosomal recessive transmission of HCM. Twenty-six HCM-related
genes were comprehensively screened for mutations in the proband with targeted second generation sequencing, and the
identified mutation was confirmed with bi-directional Sanger sequencing in all family members and 376 healthy controls.
Results: A novel missense mutation (c.1469G.T, p.Gly490Val) in exon 17 of MYBPC3 was identified. Two siblings with HCM
were homozygous for this mutation, whereas other family members were either heterozygous or wild type. Clinical
evaluation showed that both homozygotes manifested a typical HCM presentation, but none of others, including 5 adult
heterozygous mutation carriers up to 71 years of age, had any clinical evidence of HCM.
Conclusions: Our data identified a MYBPC3 mutation in HCM, which appeared autosomal recessively inherited in this family.
The absence of a family history of clinical HCM may be due to not only a de novo mutation, but also recessive mutations
that failed to produce a clinical phenotype in heterozygous family members. Therefore, consideration of recessive
mutations leading to HCM is essential for risk stratification and genetic counseling.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common
inherited heart disease and one of the common cause of sudden
cardiac death (SCD) [1]. Most cases of HCM are caused by
mutations in the genes encoding sarcomere proteins in a
Mendelian autosomal dominant pattern [1–3]. Genetic testing of
these genes in HCM patients has been recommended in the latest
guidelines, because of its significant value in diagnosis and early
identification of individuals who are at risk, especially among
family members [4,5]. However, nearly 50% HCM patients had
no apparent clinical family history of HCM. Although de novo
mutations [6,7] varied clinical penetrance, and the presence of
second mutation can attribute to parts of these cases [8–13],
recessive inheritance may be also involved.
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Methods
Subjects and Clinical Evaluation
The proband and his family were recruited at Beijing Fuwai
Hospital, Chinese Academy of Medical Sciences. Physical
examinations, resting and exercise stress M-mode, 2-D, and
Doppler echocardiograms, 12-lead ECGs, 24-hour Holter ECGs,
and cardiac magnetic resonance imaging (CMR) with late
enhancement of gadolinium (LGE) were performed for thorough
phenotype characterization of each family member. Three
hundred and seventy six individuals with normal ECGs and
echocardiograms were also included as healthy controls.
This study was performed in accordance with the principle of
the Declaration of Helsinki and approved by the Ethics
Committees of Fuwai Hospital. Written informed consents were
provided by this family and the healthy controls.
Genetic Analysis
Genomic DNA was extracted from peripheral blood leukocytes
[14]. In the proband, the entire coding sequence and the flanking
regions of 26 HCM-related genes, including MYH7, MYBPC3,
TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1, MYH6, TNNC1,
TTN, ACTN2, TCAP, VCL, ANKRD1, CAV3, CSPR3, LDB3,
MYOZ2, NEXN, JPH2, PLN, CASQ2, CALR3, PRKAG2 and
LAMP2, were enriched by using a custom designed library
(Agilent Technologies, Santa Clara, CA, USA), and subsequently
sequenced on Genome Analyzer IIx (Illumina Inc, CA, USA). The
variant was considered as disease-causing mutation if it was absent
in the genetic database of 307 Chinese healthy controls, in which
the 26 HCM-related genes were completely screened in the same
manner as did in the proband. The identified mutation in the
proband was then assessed in all family members and the other
376 healthy controls with bi-directional Sanger sequencing after
PCR amplification of corresponding exon. Previous reports of the
mutations in public polymorphism databases were determined by
searching dbSNP and 1000 Genomes at http://www.ncbi.nlm.
nih.gov/projects/SNP and http://www.1000genomes.org, respec-
tively. The pathogenicity of the mutation was predicted with
PolyPhen 2 and SIFT [15,16]. Protein sequence homology of
mutation-affected regions among species was determined with
Clustal W2 [17].
Results
Proband
The proband (III-2, 21 years old) was referred for cardiac
evaluation after the SCD of his older brother (III-1) at 23 years of
age, who had been diagnosed HCM in another hospital but had
not been offered an implantable cardioverter defibrillator (ICD)
because of the absence of clinical symptoms or family history
(medical record was not available). The proband complained
about mild chest pain after intense exertion over the past two
years. His ECG showed diffuse repolarization changes with
inverted T waves, transthoracic echocardiogram showed mid to
distal interventricular septal hypertrophy and CMR showed
hypertrophy of the mid to distal interventricular septum and the
inferior ventricular wall (Table 1).
Family History
A detailed family history revealed that the proband’s paternal
grandfather (I-3) had a 6-year history of coronary heart disease
with chest pain. There was no cardiovascular symptoms or
medical history identified in other family members. The proband’s
parents (II-1 and 2) were found to have a consanguineous
relationship (Figure 1A).
Genotype
A total of 33 nonsynonymous variants were detected in the
proband (Table S1). All the variants were present in the genetic
database of 307 controls, except a homozygous mutation
c.1469G.T within exon 17 of MYBPC3, which resulted in a
replacement of glycine at the 490th amino acid by valine (p.
Gly490Val). This novel mutation was absent from the other 376
healthy controls, and was not previously reported in the dbSNP
and 1000 Genomes public polymorphism databases. Sequence
comparisons revealed that the amino acid Gly490 is highly
conserved among species (Figure 1B), localized in an immuno-
globulin domain on MYBPC3 protein. Both PolyPhen 2 and SIFT
predicted that this mutation was pathogenic.
Genetic screening of family members showed that the proband’s
younger brother (III-3, 19 years old) was also homozygous and 6
other relatives (I-2 and 3, II-1 to 3, III-4), including the proband’s
parents, were heterozygous for Gly490Val mutation. All other
family members were normal at the 490th codon of MYBPC3
(Figure 1A).
Genotype-Phenotype Correlation
In order to confirm whether the Gly490Val mutation causes
HCM as an autosomal recessive trait, family members underwent
thorough clinical evaluations to detect the presence of HCM
(Table 1). Only the two homozygotes exhibited a typical HCM
phenotype, including inverted T waves on ECG (Figures 2A and
2B), hypertrophy of the mid to distal interventricular septum on
echocardiography (Figures 3A and 3B). CMR showed hypertro-
phy of the mid to distal interventricular septum and inferior
ventricular wall in the proband, and isolated hypertrophic septum
and inferior ventricular wall in his younger brother (Figures 4A
and 4B). Both of the two homozygotes showed preserved cardiac
function (left ventricular ejection fraction, 66% and 71%,
respectively), normal atrial and ventricular chamber dimensions,
no left ventricular outflow tract (LVOT) obstruction at rest and
after exercise, and negative LGE.
All the heterozygous mutation carriers (I-2 and I-3, II-1 to II-3,
III-4) showed no typical clinical manifestations of HCM (Table 1).
Even the oldest heterozygous mutation carriers (I-2 and I-3), who
were 71 and 62 years old, respectively, had no evidence of ECG
abnormalities (Figures 2C and 2D) or left ventricular hypertrophy
on echocardiogram (Figures 3C and 3D) and CMR. The
proband’s parents (II-1 and II-2) and one of his paternal uncles
(II-3) did not show any left ventricular hypertrophy nor LVOT
obstruction even after exercise provocation, or any arrhythmias on
24-hour Holter. CMR of II-1 to 3 showed neither structural
abnormalities nor cardiac fibrosis.
All family members without Gly490Val mutation had normal
ECGs and echocardiograms (Table 1), except the maternal
grandfather (I-1), who showed concentric hypertrophy on echo-
cardiogram with 17 mm inter ventricular septum and 15 mm left
ventricular posterior wall without abnormal T or Q waves or any
arrhythmia. However, he had a history of uncontrolled hyperten-
sion (170/100 mmHg at enrollment) for greater than 20 years.
This type of left ventricular hypertrophy is a typical cardiac
remodeling resulted from uncontrolled hypertension.
Discussion
Taking the advantage of second generation sequencing, we were
able simultaneously to screen mutations in 26 known HCM
Autosomal Recessive Transmission Results in HCM
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pathogenic genes, and identified a patient carrying a homozygous
mutation in MYBPC3 without an apparent family history of
clinical HCM. Autosomal recessive inheritance pattern of HCM
due to this MYBPC3 mutation was supported by the following
findings: (1) two clinically affected family members homozygous
for the mutation were born to clinically unaffected parents; (2) the
parents were consanguineous and heterozygous carriers of
MYBPC3 mutation; (3) all the adult family members who were
heterozygous for the mutation did not have a clinically apparent
HCM phenotype, even into their 70 s; (4) the family members who
harbored homozygous mutations expressed early-onset HCM.
Therefore, in some patients with no apparent family history of
HCM, an autosomal recessive pattern may be responsible for
disease.
MYBPC3 is a crucial component of the sarcomere and an
important regulator of muscle function. Among three different
Figure 1. Pedigree of the family with the mutation c.1469G.T (p.Gly490Val) in MYBPC3 (A). Square, male; circle, female; empty, absent of
clinical findings; black, clinically affected; ‘‘w’’, wild-type allele; ‘m’, mutant allele; ?, no genetic testing performed; black arrow, proband. Protein
sequence homology of mutation-affected regions among species (B), determined using Clustal W2. The Gly490Val substitution involves an amino
acid that is highly conserved among species.
doi:10.1371/journal.pone.0067087.g001
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MYBPC proteins, MYBPC3 is expressed exclusively in cardiac
myocytes [18,19] and its HCM-causing mutations were first
reported in 1995 [20]. Homozygous mutation in HCM was firstly
reported by Ho CY et al in 2000. They described an homozygous
Ser179Phe mutation in TNNT2 gene which caused a severe form
of HCM with striking morphological abnormalities and juvenile
lethality [21]. From then on, more homozygous mutations were
recognized either in case reports or in cohort studies. The
inheritance traits were all autosomal dominant because the
heterozygotes showed affirmatory but milder clinical evidence of
HCM than the homozygotes [21–23]. In 2002, the first autosomal
recessive transmission of HCM was reported in a family with
Glu143Lys mutation in MYL2 gene. Abnormalities in echocar-
diogram and ECG were only found in homozygous but not in
heterozygous family members [24]. Recently Gray B et al
reported a Arg162Trp mutation in TNNI3 gene could also cause
recessive HCM, but lack of clinical and genetic evaluation of old
family members [25]. MYBPC3 is one of the most common
disease-causing gene of HCM, accounting for 40–50% of known
genetic causes of HCM patients, much higher than the frequency
of mutation inMYL2 (,3%) and TNNI3 (,6%). HCM caused by
MYBPC3 mutations usually manifest lower penetrance, later onset
of disease and milder forms of disease progression in comparison
to other gene mutations (i.e., MYH7) [26,27]. Patients with
multiple mutations (i.e., compound or double heterozygotes) suffer
more severe phenotypes and increased risk of SCD [8,10,11,21].
Therefore, we postulated that some MYBPC3 mutations are
functionally so mild that they do not lead to disease unless they are
homozygous. In the present study, we screened the MYBPC3 gene
and identified a novel mutation which appeared autosomal
recessive inheritance pattern, in a manner, supported the
speculation above.
The present mutation (Gly490Val) we identified was a novel
one in the domain C3 ofMYBPC3, with small change of side chain
and kept the polarity neutral. Another mutation on the same
amino acid residue (Gly490Arg) was reported to cause HCM in
heterozygote in western population, substituting the small side
chain for a bulky side chain and changing the polarity of amino
acid residue into basic [8]. Therefore, the structural change of
domain of MYBPC3 protein, which extended into the interfila-
mental space in the motif binds to myosin S2 [28], due to mutation
Gly490Arg much more prominent than that due to mutation
Gly490Val. This might be the reason why these two kinds of
mutations on the same position presented different inheritance
patterns.
In the family described here, our documentation of inheritance
of HCM as an autosomal recessive trait had clinical implications.
The proband’s older brother had HCM in the absence of any
other obvious heart diseases, and died of SCD at young age,
suggesting that he was a highly suspicious homozygous mutation
Figure 2. ECGs of proband (III-2) and his younger brother (III-3) (A&B), both of which show diffuse repolarization changes with
large negative T waves. ECGs of I-2, I-3 and II-1 to 3 (C to G), five heterozygous mutation carriers in the oldest generation, were normal. ECG of I-1
(H), a wild type family member with 20-year uncontrolled hypertension history, whose echocardiogram showed concentric hypertrophy, was normal.
doi:10.1371/journal.pone.0067087.g002
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carrier. Therefore, the implantation of an implantable cardiover-
ter defibrillator was recommended for the two surviving homo-
zygotes in the family, the proband and his younger brother.
Heterozygous family members were felt not to require long-term
clinical follow-up.
Our results illustrate the complexity of genetic analysis for
HCM. For example, ‘‘nonpathogenic’’ variants in HCM-related
genes inherited from parents respectively may lead to HCM in the
offspring as recessive mutations. Variants found in clinically
unaffected individuals are often considered as benign polymor-
phisms because almost HCM is most commonly inherited as an
autosomal dominant trait. However, this strategy risks the missing
of recessive disease-causing mutations. This may partly explain
why disease-causing mutations were hard to be found in some
typical HCM patients and why more than half of the HCM
patients do not have obvious family history.
In conclusion, our data identified a MYBPC3 mutation
appeared to be an autosomal recessive transmission in HCM
and suggest that the inheritance pattern may be more complex
than previously thought. In clinical practice, the absence of a
family history of clinical HCM may be due to not only a de novo
mutation, but also recessive mutations that failed to produce a
clinical phenotype in heterozygous family members. Therefore,
consideration of recessive mutations leading to HCM is essential
for risk stratification and genetic counseling.
Supporting Information
Table S1 The nonsynonymous variants found in the
proband.
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